-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $54

Benzinga·07/29/2025 21:37:39
Listen to the news
Jefferies analyst Roger Song maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $45 to $54.